



**Bruce Rosengard, MD, FRCS**  
**Vice President, Global External Innovation, Medical Devices**  
**Johnson & Johnson External Innovation**

Bruce Rosengard is Vice President, Global External Innovation, Medical Devices. In this role, he sits on the Global External Innovation Leadership Team and serves as GEI's head of medical devices. Within GEI, he oversees external device opportunities to accelerate innovation, is partnering to create cross-sector R&D (starting with lung cancer), and is identifying and pursuing potentially disruptive technologies to secure J&J's future. He serves on the Medical Devices Portfolio Review Committee, which governs the early-stage portfolio for Medical Devices. In partnership with the R&D leaders of OneMD, Bruce is helping to shape a fully aligned, external innovation strategy for devices. In addition, he partners with JJDC and the Johnson & Johnson Innovation Centers to identify novel investment opportunities and creative external funding mechanisms, which will enable development of a highly differentiated, external portfolio of transformational medical devices.

Bruce brings to this role extensive experience and deep domain expertise in Medical Devices. He joined the team from Johnson & Johnson Medical Devices, where he has served as the Chief Medical Science and Technology Officer, since September 2014. During his tenure, he recruited a team of surgical scientists, who working with partners in the Medical Device franchises, created numerous early stage deals with the Innovation Centers and JJDC. Bruce also conceived of, built, and launched the Center for Device Innovation in Houston. This unique collaboration between Johnson & Johnson and the Texas Medical Center provides front-end engineering capabilities for Medical Devices, a site for developing devices for cross-sector R&D initiatives, supports selected efforts in the Consumer sector and will facilitate Enterprise Digital efforts to leverage the largest medical complex in the world.

A cardiothoracic surgeon and NIH-funded immunologist, Bruce joined Johnson & Johnson in 2014 from The Medicines Company, where he served as Vice President, New Business Ventures. He played a pivotal role in several major pharmaceutical acquisitions and was the architect of The Medicines Company's Surgical and Perioperative Care franchise. Before joining The Medicines Company, Bruce was the Surgical Director of Cardiac Transplantation at Massachusetts General Hospital and on the full-time faculty of Harvard Medical School. In addition to leading the clinical program, he ran an NIH-funded laboratory in transplantation

immunology. Prior to this, Bruce was the inaugural British Heart Foundation Professor and Chairman at the University of Cambridge, where he pioneered “beating heart” transplantation. Bruce started his career in the Departments of Surgery and Immunology at The University of Pennsylvania, where he performed the first combined heart-lung transplant at the institution, described a novel cellular mechanism responsible for triggering of transplant rejection, and patented a stem cell-based therapy to treat congestive heart failure.

Bruce was graduated summa cum laude from Tufts University with a double major in Biology and Chemistry. He obtained his MD degree from John Hopkins, where he also completed his postgraduate training in general surgery, cardiothoracic surgery, and surgical critical care. During his training, he also completed a two-year postgraduate fellowship in transplantation immunology at the National Cancer Institute. Bruce has authored more than 80 peer-reviewed publications, has given more than 40 invited talks at national or international meetings, and has served on the Boards of several professional societies.